These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25326)

  • 1. Characterization of impurities in sulfasalazine.
    Zalipsky JJ; Patel DM; Reavey-Cantwell NH
    J Pharm Sci; 1978 Mar; 67(3):387-91. PubMed ID: 25326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved method for salicylazosulfapyridine analysis and partial characterization of impurities in commercial salicylazosulfapyridine.
    Stone JC; Gorby R
    J Pharm Sci; 1974 Aug; 63(8):1296-8. PubMed ID: 4152910
    [No Abstract]   [Full Text] [Related]  

  • 3. Liquid chromatographic determination of sulfasalazine in tablets and bulk powder.
    Egli KL
    J Assoc Off Anal Chem; 1985; 68(4):803-6. PubMed ID: 2863249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and identification of three potential impurities of pholcodine bulk drug substance.
    Denk OM; Gray AI; Skellern GG; Watson DG
    J Pharm Pharmacol; 2000 Jul; 52(7):819-29. PubMed ID: 10933132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification, isolation and characterization of process related impurities in ezetimibe.
    Guntupalli S; Ray UK; Murali N; Gupta PB; Kumar VJ; Satheesh D; Islam A
    J Pharm Biomed Anal; 2014 Jan; 88():385-90. PubMed ID: 24176742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural studies of racecadotril and its process impurities by NMR and mass spectroscopy.
    Reddy KM; Babu JM; Sudhakar P; Sharma MS; Reddy GS; Vyas K
    Pharmazie; 2006 Dec; 61(12):994-8. PubMed ID: 17283655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impurities in drugs IV: Indomethacin.
    Curran NM; Lovering EG; McErlane KM; Watson JR
    J Pharm Sci; 1980 Feb; 69(2):187-9. PubMed ID: 7359321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of drug contamination from parabens in theophylline olamine.
    Juenge EC; Gurka DF; Kreienbaum MA
    J Pharm Sci; 1981 Jun; 70(6):589-93. PubMed ID: 7252796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
    J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of impurities in docetaxel.
    Vasu Dev R; Moses Babu J; Vyas K; Sai Ram P; Ramachandra P; Sekhar NM; Mohan Reddy DN; Srinivasa Rao N
    J Pharm Biomed Anal; 2006 Feb; 40(3):614-22. PubMed ID: 16330175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation, characterization and determination of trace organic impurities in FD&C red no. 40.
    Richfield-Fratz N; Baczynskyj WM; Miller GC; Bailey JE
    J Chromatogr; 1989 Apr; 467(1):167-76. PubMed ID: 2753932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation, synthesis and characterization of impurities in celecoxib, a COX-2 inhibitor.
    Satyanarayana U; Rao DS; Kumar YR; Babu JM; Kumar PR; Reddy JT
    J Pharm Biomed Anal; 2004 Jun; 35(4):951-7. PubMed ID: 15193741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impurities in illicit amphetamine: review.
    Sinnema A; Verweij AM
    Bull Narc; 1981; 33(3):37-54. PubMed ID: 7039749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impurities in drugs III: Trihexyphenidyl.
    Poirier MA; Curran NM; McErlane KM; Lovering EG
    J Pharm Sci; 1979 Sep; 68(9):1124-7. PubMed ID: 501534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
    Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
    J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of amodiaquine bulk drug impurities by liquid chromatography/ion trap mass spectrometry.
    Dongre VG; Karmuse PP; Ghugare PD; Kanojiya SK; Rawal S
    Rapid Commun Mass Spectrom; 2008 Jul; 22(14):2227-33. PubMed ID: 18543378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium.
    Saravanan M; Siva Kumari K; Pratap Reddy P; Naidu MN; Moses Babu J; Srivastava AK; Lakshmi Kumar T; Chandra Sekhar BV; Satyanarayana B
    J Pharm Biomed Anal; 2008 Nov; 48(3):708-15. PubMed ID: 18755563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI-MS(n), NMR and their synthesis.
    Kumar N; Devineni SR; Gajjala PR; Gupta DK; Bhat S; Kumar R; Dubey SK; Kumar P
    J Pharm Biomed Anal; 2016 Feb; 120():248-60. PubMed ID: 26760243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
    Görög S
    Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
    Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.